Adverse Drug Event Clinical Trial
Official title:
Ametop - Friend or Foe A Prospective Observational Study of the Incidence of Adverse Reactions With Ametop
Ametop was introduced into the formulary as it was deemed more efficacious for intravenous cannulation compared to EMLA. However, the incidences of adverse reactions seemed to be higher compared to other studies. This lead to a prospective observational study to look at the incidence and severity of skin reactions following routine clinical application of Ametop.
Ametop was introduced into the formulary as it was deemed more efficacious for intravenous
cannulation compared to EMLA. After several critical incidences of adverse reactions that
occurred with its application, a departmental audit was carried out to look at the incidence
and severity reactions with its application as well as its outcome on intravenous
cannulation. The findings of the departmental audit showed that the incidence of adverse
reactions seemed to occur more commonly compared to other studies.
A prospective observational study was carried out to look at the incidence and severity of
skin reactions following routine clinical application of Ametop.
This study aims to achieve the following:
1. Investigate the incidence and severity of adverse skin reactions following topical
application of Ametop prior to intravenous cannulation
2. Assess the success rate of intravenous cannulation
3. Identify the possible risk factors associated with adverse skin reaction.
;
Observational Model: Case-Only
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
| Completed |
NCT05007041 -
Simultaneous RZV and aIIV4 Vaccination
|
Phase 4 | |
| Suspended |
NCT02559960 -
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
|
||
| Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
| Completed |
NCT03112083 -
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
|
N/A | |
| Completed |
NCT05028361 -
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
|
Phase 4 | |
| Completed |
NCT04284553 -
Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults
|
N/A | |
| Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
| Completed |
NCT04181775 -
Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
|
||
| Completed |
NCT02906657 -
Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly
|
N/A | |
| Completed |
NCT03640273 -
Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients
|
Phase 2 | |
| Completed |
NCT02162147 -
How Safe Are Our Pediatric Emergency Departments?
|
N/A | |
| Completed |
NCT01897870 -
The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.
|
N/A | |
| Completed |
NCT03725046 -
Impact of an Optimized Communication on the Readmission for Adverse Drug Event
|
N/A | |
| Recruiting |
NCT04635956 -
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
|
Phase 2 | |
| Active, not recruiting |
NCT05538065 -
NUDGE-EHR Replication Trial at Mass General Brigham
|
N/A | |
| Completed |
NCT03442010 -
Adverse Drug Events at Emergency Department
|
||
| Recruiting |
NCT04791150 -
Rheumatologic Adverse Events and Cancer Immunotherapy
|
N/A | |
| Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
| Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A |